About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Clinical Colorectal Cancer
›
Top Articles
Clinical Colorectal Cancer
Gastroenterology
,
Oncology
3.8
(top 4%)
Impact Factor
4.1
(top 4%)
extended IF
56
(top 7%)
H-Index
1.2K
authors
1.2K
papers
19.9K
citations
2.3K
citing journals
13.9K
citing authors
Most Cited Articles of Clinical Colorectal Cancer
Title
Year
Citations
A review of the evolution of systemic chemotherapy in the management of colorectal cancer
2015
289
Colorectal Cancer: Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and Mortality
2016
193
Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer
2006
147
Bowel function 14 years after preoperative short-course radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomized trial
2015
144
Changing patterns of bone and brain metastases in patients with colorectal cancer
2005
144
Clinical management of oxaliplatin-associated neurotoxicity
2005
142
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone
2008
129
Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration
2004
128
Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer
2006
123
Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer
2004
111
Prognostic significance of miR-215 in colon cancer
2011
108
Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia
2003
108
An update on the current and emerging targeted agents in metastatic colorectal cancer
2012
98
Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab
2006
97
Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer
2005
95
Clinical significance of long intergenic noncoding RNA-p21 in colorectal cancer
2013
92
Endorectal ultrasound in the preoperative evaluation of rectal cancer
2004
91
Thymidylate synthase: a critical target for cancer chemotherapy
2002
89
Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines
2009
88
Cetuximab-induced hypomagnesemia in patients with colorectal cancer
2006
85
Epidermal growth factor receptor as a therapeutic target in colorectal cancer
2003
85
Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer
2008
82
PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer
2012
80
Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer
2007
80
Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer
2014
77
previous
2012
2013
2014
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.